APO Research
Talk to an analyst

APO RESEARCH · REPORT

Menstrual Regulating Drug

Compare research editions
View pricing & licenses

Selected research

Industry Research

Menstrual Regulating Drug Industry Research Report 2026

27 December 2025138 pages

Choose your research edition.

Industry ResearchMenstrual Regulating Drug Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal Menstrual Regulating Drug Industry Growth and Trends Forecast to 2032118 pages · $3,450 USDMarket StructureGlobal Menstrual Regulating Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Menstrual Regulating Drug Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Menstrual Regulating Drug Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Menstrual Regulating Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Menstrual Regulating Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Menstrual Regulating Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Menstrual Regulating Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Menstrual Regulating Drug include Teva Pharmaceutical Industries Ltd., Johnson & Johnson, Merck & Co., Inc., Mylan N.V., Pfizer Inc., Bayer AG, AbbVie Inc., Sun Pharmaceutical Industries Ltd. and Sandoz International GmbH, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Menstrual Regulating Drug market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Menstrual Regulating Drug Market by Company

Teva Pharmaceutical Industries Ltd.

Johnson & Johnson

Merck & Co., Inc.

Mylan N.V.

Pfizer Inc.

Bayer AG

AbbVie Inc.

Sun Pharmaceutical Industries Ltd.

Sandoz International GmbH

Novartis AG

Lupin Limited

HRA Pharma

GlaxoSmithKline plc

Dr. Reddy's Laboratories Ltd.

Allergan plc

Menstrual Regulating Drug Segment by Type

Contraceptive Pills

Non-contraceptive Pills

Menstrual Regulating Drug Segment by Application

Irregular Menstruation

Menstrual Pain

Others

Menstrual Regulating Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Menstrual Regulating Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Menstrual Regulating Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Menstrual Regulating Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Menstrual Regulating Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Menstrual Regulating Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Menstrual Regulating Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Menstrual Regulating Drug Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Menstrual Regulating Drug Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Menstrual Regulating Drug Sales Market Share by Manufacturers (2021-2026) Table 8. Global Menstrual Regulating Drug Revenue of Manufacturers (2021-2026) Table 9. Global Menstrual Regulating Drug Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Menstrual Regulating Drug Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Menstrual Regulating Drug Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Menstrual Regulating Drug, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Menstrual Regulating Drug, Product Type & Application Table 14. Global Menstrual Regulating Drug Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Menstrual Regulating Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Teva Pharmaceutical Industries Ltd. Company Information Table 19. Teva Pharmaceutical Industries Ltd. Business Overview Table 20. Teva Pharmaceutical Industries Ltd. Menstrual Regulating Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Teva Pharmaceutical Industries Ltd. Menstrual Regulating Drug Product Portfolio Table 22. Teva Pharmaceutical Industries Ltd. Recent Developments Table 23. Johnson & Johnson Company Information Table 24. Johnson & Johnson Business Overview Table 25. Johnson & Johnson Menstrual Regulating Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Johnson & Johnson Menstrual Regulating Drug Product Portfolio Table 27. Johnson & Johnson Recent Developments Table 28. Merck & Co., Inc. Company Information Table 29. Merck & Co., Inc. Business Overview Table 30. Merck & Co., Inc. Menstrual Regulating Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Merck & Co., Inc. Menstrual Regulating Drug Product Portfolio Table 32. Merck & Co., Inc. Recent Developments Table 33. Mylan N.V. Company Information Table 34. Mylan N.V. Business Overview Table 35. Mylan N.V. Menstrual Regulating Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Mylan N.V. Menstrual Regulating Drug Product Portfolio Table 37. Mylan N.V. Recent Developments Table 38. Pfizer Inc. Company Information Table 39. Pfizer Inc. Business Overview Table 40. Pfizer Inc. Menstrual Regulating Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Pfizer Inc. Menstrual Regulating Drug Product Portfolio Table 42. Pfizer Inc. Recent Developments Table 43. Bayer AG Company Information Table 44. Bayer AG Business Overview Table 45. Bayer AG Menstrual Regulating Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Bayer AG Menstrual Regulating Drug Product Portfolio Table 47. Bayer AG Recent Developments Table 48. AbbVie Inc. Company Information Table 49. AbbVie Inc. Business Overview Table 50. AbbVie Inc. Menstrual Regulating Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. AbbVie Inc. Menstrual Regulating Drug Product Portfolio Table 52. AbbVie Inc. Recent Developments Table 53. Sun Pharmaceutical Industries Ltd. Company Information Table 54. Sun Pharmaceutical Industries Ltd. Business Overview Table 55. Sun Pharmaceutical Industries Ltd. Menstrual Regulating Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Sun Pharmaceutical Industries Ltd. Menstrual Regulating Drug Product Portfolio Table 57. Sun Pharmaceutical Industries Ltd. Recent Developments Table 58. Sandoz International GmbH Company Information Table 59. Sandoz International GmbH Business Overview Table 60. Sandoz International GmbH Menstrual Regulating Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Sandoz International GmbH Menstrual Regulating Drug Product Portfolio Table 62. Sandoz International GmbH Recent Developments Table 63. Novartis AG Company Information Table 64. Novartis AG Business Overview Table 65. Novartis AG Menstrual Regulating Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Novartis AG Menstrual Regulating Drug Product Portfolio Table 67. Novartis AG Recent Developments Table 68. Lupin Limited Company Information Table 69. Lupin Limited Business Overview Table 70. Lupin Limited Menstrual Regulating Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Lupin Limited Menstrual Regulating Drug Product Portfolio Table 72. Lupin Limited Recent Developments Table 73. HRA Pharma Company Information Table 74. HRA Pharma Business Overview Table 75. HRA Pharma Menstrual Regulating Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. HRA Pharma Menstrual Regulating Drug Product Portfolio Table 77. HRA Pharma Recent Developments Table 78. GlaxoSmithKline plc Company Information Table 79. GlaxoSmithKline plc Business Overview Table 80. GlaxoSmithKline plc Menstrual Regulating Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. GlaxoSmithKline plc Menstrual Regulating Drug Product Portfolio Table 82. GlaxoSmithKline plc Recent Developments Table 83. Dr. Reddy's Laboratories Ltd. Company Information Table 84. Dr. Reddy's Laboratories Ltd. Business Overview Table 85. Dr. Reddy's Laboratories Ltd. Menstrual Regulating Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Dr. Reddy's Laboratories Ltd. Menstrual Regulating Drug Product Portfolio Table 87. Dr. Reddy's Laboratories Ltd. Recent Developments Table 88. Allergan plc Company Information Table 89. Allergan plc Business Overview Table 90. Allergan plc Menstrual Regulating Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Allergan plc Menstrual Regulating Drug Product Portfolio Table 92. Allergan plc Recent Developments Table 93. Global Menstrual Regulating Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 94. Global Menstrual Regulating Drug Sales by Region (2021-2026) & (K Units) Table 95. Global Menstrual Regulating Drug Sales Market Share by Region (2021-2026) Table 96. Global Menstrual Regulating Drug Sales by Region (2027-2032) & (K Units) Table 97. Global Menstrual Regulating Drug Sales Market Share by Region (2027-2032) Table 98. Global Menstrual Regulating Drug Revenue by Region (2021-2026) & (US$ Million) Table 99. Global Menstrual Regulating Drug Revenue Market Share by Region (2021-2026) Table 100. Global Menstrual Regulating Drug Revenue by Region (2027-2032) & (US$ Million) Table 101. Global Menstrual Regulating Drug Revenue Market Share by Region (2027-2032) Table 102. North America Menstrual Regulating Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. North America Menstrual Regulating Drug Sales by Country (2021-2026) & (K Units) Table 104. North America Menstrual Regulating Drug Sales by Country (2027-2032) & (K Units) Table 105. North America Menstrual Regulating Drug Revenue by Country (2021-2026) & (US$ Million) Table 106. North America Menstrual Regulating Drug Revenue by Country (2027-2032) & (US$ Million) Table 107. Europe Menstrual Regulating Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. Europe Menstrual Regulating Drug Sales by Country (2021-2026) & (K Units) Table 109. Europe Menstrual Regulating Drug Sales by Country (2027-2032) & (K Units) Table 110. Europe Menstrual Regulating Drug Revenue by Country (2021-2026) & (US$ Million) Table 111. Europe Menstrual Regulating Drug Revenue by Country (2027-2032) & (US$ Million) Table 112. Asia Pacific Menstrual Regulating Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. Asia Pacific Menstrual Regulating Drug Sales by Country (2021-2026) & (K Units) Table 114. Asia Pacific Menstrual Regulating Drug Sales by Country (2027-2032) & (K Units) Table 115. Asia Pacific Menstrual Regulating Drug Revenue by Country (2021-2026) & (US$ Million) Table 116. Asia Pacific Menstrual Regulating Drug Revenue by Country (2027-2032) & (US$ Million) Table 117. South America Menstrual Regulating Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. South America Menstrual Regulating Drug Sales by Country (2021-2026) & (K Units) Table 119. South America Menstrual Regulating Drug Sales by Country (2027-2032) & (K Units) Table 120. South America Menstrual Regulating Drug Revenue by Country (2021-2026) & (US$ Million) Table 121. South America Menstrual Regulating Drug Revenue by Country (2027-2032) & (US$ Million) Table 122. Middle East and Africa Menstrual Regulating Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. Middle East and Africa Menstrual Regulating Drug Sales by Country (2021-2026) & (K Units) Table 124. Middle East and Africa Menstrual Regulating Drug Sales by Country (2027-2032) & (K Units) Table 125. Middle East and Africa Menstrual Regulating Drug Revenue by Country (2021-2026) & (US$ Million) Table 126. Middle East and Africa Menstrual Regulating Drug Revenue by Country (2027-2032) & (US$ Million) Table 127. Global Menstrual Regulating Drug Sales by Type (2021-2026) & (K Units) Table 128. Global Menstrual Regulating Drug Sales by Type (2027-2032) & (K Units) Table 129. Global Menstrual Regulating Drug Sales Market Share by Type (2021-2026) Table 130. Global Menstrual Regulating Drug Sales Market Share by Type (2027-2032) Table 131. Global Menstrual Regulating Drug Revenue by Type (2021-2026) & (US$ Million) Table 132. Global Menstrual Regulating Drug Revenue by Type (2027-2032) & (US$ Million) Table 133. Global Menstrual Regulating Drug Revenue Market Share by Type (2021-2026) Table 134. Global Menstrual Regulating Drug Revenue Market Share by Type (2027-2032) Table 135. Global Menstrual Regulating Drug Price by Type (2021-2026) & (US$/Unit) Table 136. Global Menstrual Regulating Drug Price by Type (2027-2032) & (US$/Unit) Table 137. Global Menstrual Regulating Drug Sales by Application (2021-2026) & (K Units) Table 138. Global Menstrual Regulating Drug Sales by Application (2027-2032) & (K Units) Table 139. Global Menstrual Regulating Drug Sales Market Share by Application (2021-2026) Table 140. Global Menstrual Regulating Drug Sales Market Share by Application (2027-2032) Table 141. Global Menstrual Regulating Drug Revenue by Application (2021-2026) & (US$ Million) Table 142. Global Menstrual Regulating Drug Revenue by Application (2027-2032) & (US$ Million) Table 143. Global Menstrual Regulating Drug Revenue Market Share by Application (2021-2026) Table 144. Global Menstrual Regulating Drug Revenue Market Share by Application (2027-2032) Table 145. Global Menstrual Regulating Drug Price by Application (2021-2026) & (US$/Unit) Table 146. Global Menstrual Regulating Drug Price by Application (2027-2032) & (US$/Unit) Table 147. Key Raw Materials Table 148. Raw Materials Key Suppliers Table 149. Menstrual Regulating Drug Distributors List Table 150. Menstrual Regulating Drug Customers List Table 151. Menstrual Regulating Drug Industry Trends Table 152. Menstrual Regulating Drug Industry Drivers Table 153. Menstrual Regulating Drug Industry Restraints Table 154. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Menstrual Regulating Drug Product Image Figure 5. Global Menstrual Regulating Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Menstrual Regulating Drug Market Size (2021-2032) & (US$ Million) Figure 7. Global Menstrual Regulating Drug Sales (2021-2032) & (K Units) Figure 8. Global Menstrual Regulating Drug Average Price (US$/Unit) & (2021-2032) Figure 9. Contraceptive Pills Product Image Figure 10. Non-contraceptive Pills Product Image Figure 11. Irregular Menstruation Product Image Figure 12. Menstrual Pain Product Image Figure 13. Others Product Image Figure 14. Global Menstrual Regulating Drug Revenue Share by Manufacturers in 2025 Figure 15. Global Manufacturers of Menstrual Regulating Drug, Manufacturing Sites & Headquarters Figure 16. Global Top 5 and 10 Menstrual Regulating Drug Players Market Share by Revenue in 2025 Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Menstrual Regulating Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 19. Global Menstrual Regulating Drug Sales by Region in 2025 Figure 20. Global Menstrual Regulating Drug Revenue by Region in 2025 Figure 21. North America Menstrual Regulating Drug Market Size by Country in 2025 Figure 22. North America Menstrual Regulating Drug Sales Market Share by Country (2021-2032) Figure 23. North America Menstrual Regulating Drug Revenue Market Share by Country (2021-2032) Figure 24. United States Menstrual Regulating Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Canada Menstrual Regulating Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Mexico Menstrual Regulating Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Europe Menstrual Regulating Drug Market Size by Country in 2025 Figure 28. Europe Menstrual Regulating Drug Sales Market Share by Country (2021-2032) Figure 29. Europe Menstrual Regulating Drug Revenue Market Share by Country (2021-2032) Figure 30. Germany Menstrual Regulating Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. France Menstrual Regulating Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. U.K. Menstrual Regulating Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Italy Menstrual Regulating Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Russia Menstrual Regulating Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Spain Menstrual Regulating Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Netherlands Menstrual Regulating Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Switzerland Menstrual Regulating Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Sweden Menstrual Regulating Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Poland Menstrual Regulating Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Asia Pacific Menstrual Regulating Drug Market Size by Country in 2025 Figure 41. Asia Pacific Menstrual Regulating Drug Sales Market Share by Country (2021-2032) Figure 42. Asia Pacific Menstrual Regulating Drug Revenue Market Share by Country (2021-2032) Figure 43. China Menstrual Regulating Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Japan Menstrual Regulating Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. South Korea Menstrual Regulating Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. India Menstrual Regulating Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Australia Menstrual Regulating Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Taiwan Menstrual Regulating Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia Menstrual Regulating Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia Menstrual Regulating Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. South America Menstrual Regulating Drug Market Size by Country in 2025 Figure 52. South America Menstrual Regulating Drug Sales Market Share by Country (2021-2032) Figure 53. South America Menstrual Regulating Drug Revenue Market Share by Country (2021-2032) Figure 54. Brazil Menstrual Regulating Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Argentina Menstrual Regulating Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Chile Menstrual Regulating Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Middle East and Africa Menstrual Regulating Drug Market Size by Country in 2025 Figure 58. Middle East and Africa Menstrual Regulating Drug Sales Market Share by Country (2021-2032) Figure 59. Middle East and Africa Menstrual Regulating Drug Revenue Market Share by Country (2021-2032) Figure 60. Egypt Menstrual Regulating Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. South Africa Menstrual Regulating Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Israel Menstrual Regulating Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Türkiye Menstrual Regulating Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. GCC Countries Menstrual Regulating Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Global Menstrual Regulating Drug Sales Market Share by Type (2021-2032) Figure 66. Global Menstrual Regulating Drug Revenue Market Share by Type (2021-2032) Figure 67. Global Menstrual Regulating Drug Price (US$/Unit) by Type (2021-2032) Figure 68. Global Menstrual Regulating Drug Sales Market Share by Application (2021-2032) Figure 69. Global Menstrual Regulating Drug Revenue Market Share by Application (2021-2032) Figure 70. Global Menstrual Regulating Drug Price (US$/Unit) by Application (2021-2032) Figure 71. Menstrual Regulating Drug Value Chain Figure 72. Menstrual Regulating Drug Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Menstrual Regulating Drug Industry Opportunities and Challenges

Scope & coverage.

Types
  • Contraceptive Pills
  • Non-contraceptive Pills
Applications
  • Irregular Menstruation
  • Menstrual Pain
  • Others
Companies covered
  • Teva Pharmaceutical Industries Ltd.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mylan N.V.
  • Pfizer Inc.
  • Bayer AG
  • AbbVie Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Novartis AG
  • Lupin Limited
  • HRA Pharma
  • GlaxoSmithKline plc
  • Dr. Reddy's Laboratories Ltd.
  • Allergan plc

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Menstrual Regulating Drug Market Size (2021-2032)
  4. 2.2.2 Global Menstrual Regulating Drug Sales (2021-2032)
  5. 2.2.3 Global Menstrual Regulating Drug Market Average Price (2021-2032)
  6. 2.3 Menstrual Regulating Drug by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Contraceptive Pills
  9. 2.3.3 Non-contraceptive Pills
  10. 2.4 Menstrual Regulating Drug by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Irregular Menstruation
  13. 2.4.3 Menstrual Pain
  14. 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Menstrual Regulating Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Menstrual Regulating Drug Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Menstrual Regulating Drug Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Menstrual Regulating Drug Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Menstrual Regulating Drug Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Menstrual Regulating Drug, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Menstrual Regulating Drug, Product Type & Application
  8. 3.8 Global Manufacturers of Menstrual Regulating Drug, Established Date
  9. 3.9 Global Menstrual Regulating Drug Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Teva Pharmaceutical Industries Ltd.
  2. 4.1.1 Teva Pharmaceutical Industries Ltd. Company Information
  3. 4.1.2 Teva Pharmaceutical Industries Ltd. Business Overview
  4. 4.1.3 Teva Pharmaceutical Industries Ltd. Menstrual Regulating Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Teva Pharmaceutical Industries Ltd. Menstrual Regulating Drug Product Portfolio
  6. 4.1.5 Teva Pharmaceutical Industries Ltd. Recent Developments
  7. 4.2 Johnson & Johnson
  8. 4.2.1 Johnson & Johnson Company Information
  9. 4.2.2 Johnson & Johnson Business Overview
  10. 4.2.3 Johnson & Johnson Menstrual Regulating Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Johnson & Johnson Menstrual Regulating Drug Product Portfolio
  12. 4.2.5 Johnson & Johnson Recent Developments
  13. 4.3 Merck & Co., Inc.
  14. 4.3.1 Merck & Co., Inc. Company Information
  15. 4.3.2 Merck & Co., Inc. Business Overview
  16. 4.3.3 Merck & Co., Inc. Menstrual Regulating Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Merck & Co., Inc. Menstrual Regulating Drug Product Portfolio
  18. 4.3.5 Merck & Co., Inc. Recent Developments
  19. 4.4 Mylan N.V.
  20. 4.4.1 Mylan N.V. Company Information
  21. 4.4.2 Mylan N.V. Business Overview
  22. 4.4.3 Mylan N.V. Menstrual Regulating Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Mylan N.V. Menstrual Regulating Drug Product Portfolio
  24. 4.4.5 Mylan N.V. Recent Developments
  25. 4.5 Pfizer Inc.
  26. 4.5.1 Pfizer Inc. Company Information
  27. 4.5.2 Pfizer Inc. Business Overview
  28. 4.5.3 Pfizer Inc. Menstrual Regulating Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Pfizer Inc. Menstrual Regulating Drug Product Portfolio
  30. 4.5.5 Pfizer Inc. Recent Developments
  31. 4.6 Bayer AG
  32. 4.6.1 Bayer AG Company Information
  33. 4.6.2 Bayer AG Business Overview
  34. 4.6.3 Bayer AG Menstrual Regulating Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Bayer AG Menstrual Regulating Drug Product Portfolio
  36. 4.6.5 Bayer AG Recent Developments
  37. 4.7 AbbVie Inc.
  38. 4.7.1 AbbVie Inc. Company Information
  39. 4.7.2 AbbVie Inc. Business Overview
  40. 4.7.3 AbbVie Inc. Menstrual Regulating Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 AbbVie Inc. Menstrual Regulating Drug Product Portfolio
  42. 4.7.5 AbbVie Inc. Recent Developments
  43. 4.8 Sun Pharmaceutical Industries Ltd.
  44. 4.8.1 Sun Pharmaceutical Industries Ltd. Company Information
  45. 4.8.2 Sun Pharmaceutical Industries Ltd. Business Overview
  46. 4.8.3 Sun Pharmaceutical Industries Ltd. Menstrual Regulating Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Sun Pharmaceutical Industries Ltd. Menstrual Regulating Drug Product Portfolio
  48. 4.8.5 Sun Pharmaceutical Industries Ltd. Recent Developments
  49. 4.9 Sandoz International GmbH
  50. 4.9.1 Sandoz International GmbH Company Information
  51. 4.9.2 Sandoz International GmbH Business Overview
  52. 4.9.3 Sandoz International GmbH Menstrual Regulating Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Sandoz International GmbH Menstrual Regulating Drug Product Portfolio
  54. 4.9.5 Sandoz International GmbH Recent Developments
  55. 4.10 Novartis AG
  56. 4.10.1 Novartis AG Company Information
  57. 4.10.2 Novartis AG Business Overview
  58. 4.10.3 Novartis AG Menstrual Regulating Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Novartis AG Menstrual Regulating Drug Product Portfolio
  60. 4.10.5 Novartis AG Recent Developments
  61. 4.11 Lupin Limited
  62. 4.11.1 Lupin Limited Company Information
  63. 4.11.2 Lupin Limited Business Overview
  64. 4.11.3 Lupin Limited Menstrual Regulating Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Lupin Limited Menstrual Regulating Drug Product Portfolio
  66. 4.11.5 Lupin Limited Recent Developments
  67. 4.12 HRA Pharma
  68. 4.12.1 HRA Pharma Company Information
  69. 4.12.2 HRA Pharma Business Overview
  70. 4.12.3 HRA Pharma Menstrual Regulating Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 HRA Pharma Menstrual Regulating Drug Product Portfolio
  72. 4.12.5 HRA Pharma Recent Developments
  73. 4.13 GlaxoSmithKline plc
  74. 4.13.1 GlaxoSmithKline plc Company Information
  75. 4.13.2 GlaxoSmithKline plc Business Overview
  76. 4.13.3 GlaxoSmithKline plc Menstrual Regulating Drug Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 GlaxoSmithKline plc Menstrual Regulating Drug Product Portfolio
  78. 4.13.5 GlaxoSmithKline plc Recent Developments
  79. 4.14 Dr. Reddy's Laboratories Ltd.
  80. 4.14.1 Dr. Reddy's Laboratories Ltd. Company Information
  81. 4.14.2 Dr. Reddy's Laboratories Ltd. Business Overview
  82. 4.14.3 Dr. Reddy's Laboratories Ltd. Menstrual Regulating Drug Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Dr. Reddy's Laboratories Ltd. Menstrual Regulating Drug Product Portfolio
  84. 4.14.5 Dr. Reddy's Laboratories Ltd. Recent Developments
  85. 4.15 Allergan plc
  86. 4.15.1 Allergan plc Company Information
  87. 4.15.2 Allergan plc Business Overview
  88. 4.15.3 Allergan plc Menstrual Regulating Drug Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Allergan plc Menstrual Regulating Drug Product Portfolio
  90. 4.15.5 Allergan plc Recent Developments
5 Global Menstrual Regulating Drug Market Scenario by Region
  1. 5.1 Global Menstrual Regulating Drug Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Menstrual Regulating Drug Sales by Region: 2021-2032
  3. 5.2.1 Global Menstrual Regulating Drug Sales by Region: 2021-2026
  4. 5.2.2 Global Menstrual Regulating Drug Sales by Region: 2027-2032
  5. 5.3 Global Menstrual Regulating Drug Revenue by Region: 2021-2032
  6. 5.3.1 Global Menstrual Regulating Drug Revenue by Region: 2021-2026
  7. 5.3.2 Global Menstrual Regulating Drug Revenue by Region: 2027-2032
  8. 5.4 North America Menstrual Regulating Drug Market Facts & Figures by Country
  9. 5.4.1 North America Menstrual Regulating Drug Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Menstrual Regulating Drug Sales by Country (2021-2032)
  11. 5.4.3 North America Menstrual Regulating Drug Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Menstrual Regulating Drug Market Facts & Figures by Country
  16. 5.5.1 Europe Menstrual Regulating Drug Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Menstrual Regulating Drug Sales by Country (2021-2032)
  18. 5.5.3 Europe Menstrual Regulating Drug Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Menstrual Regulating Drug Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Menstrual Regulating Drug Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Menstrual Regulating Drug Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Menstrual Regulating Drug Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Menstrual Regulating Drug Market Facts & Figures by Country
  41. 5.7.1 South America Menstrual Regulating Drug Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Menstrual Regulating Drug Sales by Country (2021-2032)
  43. 5.7.3 South America Menstrual Regulating Drug Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Menstrual Regulating Drug Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Menstrual Regulating Drug Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Menstrual Regulating Drug Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Menstrual Regulating Drug Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Menstrual Regulating Drug Sales by Type (2021-2032)
  2. 6.1.1 Global Menstrual Regulating Drug Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Menstrual Regulating Drug Sales Market Share by Type (2021-2032)
  4. 6.2 Global Menstrual Regulating Drug Revenue by Type (2021-2032)
  5. 6.2.1 Global Menstrual Regulating Drug Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Menstrual Regulating Drug Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Menstrual Regulating Drug Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Menstrual Regulating Drug Sales by Application (2021-2032)
  2. 7.1.1 Global Menstrual Regulating Drug Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Menstrual Regulating Drug Sales Market Share by Application (2021-2032)
  4. 7.2 Global Menstrual Regulating Drug Revenue by Application (2021-2032)
  5. 7.2.1 Global Menstrual Regulating Drug Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Menstrual Regulating Drug Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Menstrual Regulating Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Menstrual Regulating Drug Value Chain Analysis
  2. 8.1.1 Menstrual Regulating Drug Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Menstrual Regulating Drug Production Mode & Process
  5. 8.2 Menstrual Regulating Drug Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Menstrual Regulating Drug Distributors
  8. 8.2.3 Menstrual Regulating Drug Customers
9 Global Menstrual Regulating Drug Analyzing Market Dynamics
  1. 9.1 Menstrual Regulating Drug Industry Trends
  2. 9.2 Menstrual Regulating Drug Industry Drivers
  3. 9.3 Menstrual Regulating Drug Industry Opportunities and Challenges
  4. 9.4 Menstrual Regulating Drug Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst